Albany Molecular Research (AMRI) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
AMRI Announces Third Quarter 2016 Results
November 8, 2016 7:30 AM ESTALBANY, N.Y., Nov. 8, 2016 /PRNewswire/ --Â AMRI (NASDAQ: AMRI) today reported financial and operating results for the third quarter ended September 30, 2016 and reiterated its outlook for 2016.
Highlights:
Contract revenue of $151.7 million, up 50% from the third quarter 2015 Reported contract margins of 19%; non-GAAP contract margins of 30% Reported basic and diluted EPS $(0.57); non-GAAP diluted EPS of $0.17 Recurring royalty revenue of $1.1 million Reported net loss of $(23.4) million; non-GAAP net income of $7.2 million Adjusted EBITDA of $25.5 million, up 55% from the third quarter 2015 Reaffirms 2016... More